Given that daily ∼2 Gy fractions are most widely used clinically,Miller et al. developed a long-circulating prodrug, wherein MMAE orDox prodrugs are conjugated to albumin, antibodies, or nanoparticlesvia a phenyl azide linker, enabling tumor targeting and extended circulationof the prodrug in vivo. This evidence concerns the gene ALB and neoplasm.